

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E11/21 - Hormones 1

Deadline: 09.02.2021

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Traceability																	
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}		
(121) Total T3	[nmol/L]				2							2	2	100%									0	
Samples and groups																								
Sample A		7,63	0,58	7,6	2							2	2	100%									0	
Other					2	0						2												
							1x 4/1, 1x 4/12																	
Sample B		2,18	0,08	3,7	2							2	2	100%									0	
Other					2	0						2												
							1x 4/1, 1x 4/12																	
(122) Total T4	[nmol/L]				3							3	2	67%								3	2	67%
Samples and groups																								
Sample A		124	16	13	3							3	2	67% CRV	151	2,0	17%	125	177		3	2	67%	
Other					3	0						3										3		
							1x 4/1, 1x 4/12, 1x 4/60								1x 4/1, 1x 4/12, 1x 4/60									
Sample B		218	23	11	3							3	2	67% CRV	249,5	2,5	17%	207	292		3	2	67%	
Other					3	0						3										3		
							1x 4/1, 1x 4/12, 1x 4/60								1x 4/1, 1x 4/12, 1x 4/60									
(123) TSH	[mU/L]				23							23	21	91%									0	
Samples and groups																								
Sample A		19,3	2,6	14	23							23	21	91%									0	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		16,7	1,3	7,6	7	0	CVPG	16,7	0,12	14%	14,3	19,1		7										
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		18,7	0,82	4,4	5	0	CVPG	19	0,20	14%	16,3	21,7		5										
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		21,0	0,53	2,5	9	0	CVPG	21,3	0,065	14%	18,3	24,3		9										
Other					2	0								2										
							1x 3/25, 1x 4/179																	
Sample B		10,1	1,5	15	23							23	21	91%									0	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		8,56	0,38	4,4	7	0	CVPG	8,72	0,065	14%	7,49	9,95		7										
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		9,58	0,28	2,9	5	0	CVPG	9,72	0,11	14%	8,35	11,1		5										
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		10,9	0,38	3,5	9	0	CVPG	11,1	0,036	14%	9,54	12,7		9										
Other					2	0								2										
							1x 3/25, 1x 4/179																	
(124) Free T4	[pmol/L]				23							23	18	78%									0	
Samples and groups																								
Sample A		26,6	5,6	21	23							23	21	91%									0	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		20,4	1,1	5,6	7	0	CVPG	20	0,19	13%	17,4	22,6		7										
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		26,1	2,0	7,8	5	0	CVPG	26,1	0,35	13%	22,7	29,5		5										
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		31,6	0,85	2,7	9	0	CVPG	32,2	0,15	13%	28	36,4		9										

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E11/21 - Hormones 1

Deadline: 09.02.2021

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(124) Free T4					23							23	18	78%							0		
Samples and groups	[pmol/L]																						
Sample A		26,6	5,6	21	23							23	21	91%							0		
Other					2	0						2											
							1x 3/25, 1x 4/179																
Sample B		55,2	14	26	23							23	19	83%							0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		39,4	2,7	6,7	7	0	CVPG	38,2	0,69	13%	33,2	43,2		7									
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		54,6	1,8	3,3	5	0	CVPG	52,4	0,90	13%	45,5	59,3		5									
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		68,8	1,3	1,9	9	0	CVPG	71,7	0,50	13%	62,3	81,1		9									
Other					2	0								2									
							1x 3/25, 1x 4/179																
(125) Free T3					18							18	16	89%							0		
Samples and groups	[pmol/L]																						
Sample A		32,3	7,5	23	18							18	16	89%							0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		29,2	2,2	7,5	6	0	CVPG	28,7	0,42	15%	24,3	33,1		6									
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		38,9	2,8	7,3	6	0	CVPG	37,8	0,11	15%	32,1	43,5		6									
Other					6	0								6									
							4x 4/12, 1x 4/154, 1x 4/179																
Sample B		9,15	1,6	17	18							18	16	89%							0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		8,23	0,27	3,2	6	0	CVPG	7,9	0,082	15%	6,71	9,09		6									
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		10,7	0,74	6,9	6	0	CVPG	10,3	0,037	15%	8,75	11,9		6									
Other					6	0								6									
							4x 4/12, 1x 4/154, 1x 4/179																
(200) Ferritin					20							19	14	74%							0		
Samples and groups	[µg/L]																						
Sample A		578	140	24	20							19	18	95%							0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		720	59	8,2	6	0	CVPG	691	12	24%	525	857		6									
Other					14	0								13									
							3x 4/12, 3x 4/60, 1x 4/179, 1x 6/1, 3x 6/58, 3x 6/60																
Sample B		77,7	26	34	20							19	14	74%							0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		66,7	25	37	6	0	CVPG	74,3	2,3	24%	56,4	92,2		6									
Other					14	0								13									
							3x 4/12, 3x 4/60, 1x 4/179, 1x 6/1, 3x 6/58, 3x 6/60																
(301) Cortisol					10							10	7	70%							10	8	80%
Samples and groups	[nmol/L]																						
Sample A		314	50	16	10							10	7	70% CRV	302,4	6,5	22%	235	369	10	8	80%	
Other					10	0						10									10		
							3x 4/1, 3x 4/12, 4x 4/60																
Sample B		984	130	13	10							10	7	70% CRV	925,9	9,5	22%	722	1130	10	9	90%	
Other					10	0						10									10		
							3x 4/1, 3x 4/12, 4x 4/60																

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E11/21 - Hormones 1

Deadline: 09.02.2021

Test	[unit]	Comparability					Traceability																	
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}		
(302) 17-beta-estradiol	[pmol/L]				13							13	13	100%							13	13	100%	
Samples and groups																								
Sample A		1100	130	11	13							13	13	100%	CRV	1038	11	30%	726	1350	13	13	100%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		1110	62	5,5	5	0	CVPG	1140	5,8	22%	889	1400									5			
Other					8	0							8								8			
								1x 3/25, 3x 4/1, 3x 4/12, 1x 4/179								1x 3/25, 3x 4/1, 3x 4/12, 1x 4/179								
Sample B		653	46	7,0	13							13	13	100%	CRV	651,3	8,2	30%	455	847	13	13	100%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		658	37	5,6	5	0	CVPG	669	3,9	22%	521	817									5			
Other					8	0							8								8			
								1x 3/25, 3x 4/1, 3x 4/12, 1x 4/179								1x 3/25, 3x 4/1, 3x 4/12, 1x 4/179								
(303) Aldosterone	[nmol/L]				5							4	3	75%							0			
Samples and groups																								
Sample A		0,340	0,04	13	5							4	4	100%							0			
Other					5	0						4												
								1x 1/36, 1x 1/218, 1x 2/66, 2x 4/164																
Sample B		1,59	0,25	16	5							4	3	75%							0			
Other					5	0						4												
								1x 1/36, 1x 1/218, 1x 2/66, 2x 4/164																
(304) Progesterone	[nmol/L]				14							14	14	100%							14	12	86%	
Samples and groups																								
Sample A		60,7	10	17	14							14	14	100%	CRV	59,2	0,69	26%	43,8	74,6	14	12	86%	
Other					14	0						14									14			
								1x 3/25, 4x 4/1, 4x 4/12, 4x 4/60, 1x 4/179								1x 3/25, 4x 4/1, 4x 4/12, 4x 4/60, 1x 4/179								
Sample B		13,9	1,7	12	14							14	14	100%	CRV	13,5	0,20	26%	9,99	17,1	14	13	93%	
Other					14	0						14									14			
								1x 3/25, 4x 4/1, 4x 4/12, 4x 4/60, 1x 4/179								1x 3/25, 4x 4/1, 4x 4/12, 4x 4/60, 1x 4/179								
(305) Testosterone	[nmol/L]				14							14	12	86%							14	12	86%	
Samples and groups																								
Sample A		37,5	5,4	14	14							14	12	86%	CRV	36,47	0,54	30%	25,5	47,5	14	13	93%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		35,0	1,8	5,0	5	0	CVPG	34,6	0,70	22%	26,9	42,3									5			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		38,3	1,0	2,6	6	0	CVPG	39,7	0,28	22%	30,9	48,5									6			
Other					3	0							3								3			
								1x 3/25, 1x 4/1, 1x 4/179								1x 3/25, 1x 4/1, 1x 4/179								
Sample B		22,1	3,0	14	14							14	12	86%	CRV	21,46	0,22	30%	15	27,9	14	12	86%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		20,0	0,96	4,8	5	0	CVPG	20,1	0,44	22%	15,6	24,6									5			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		22,6	0,64	2,8	6	0	CVPG	23,2	0,14	22%	18	28,4									6			
Other					3	0							3								3			
								1x 3/25, 1x 4/1, 1x 4/179								1x 3/25, 1x 4/1, 1x 4/179								
(306) 17-OH-progesterone	[nmol/L]				2							2	2	100%							2	2	100%	
Samples and groups																								
Sample A		22,7	0,04	0,20	2							2	2	100%	CRV	27,79	0,36	44%	15,5	40,1	2	2	100%	
Other					2	0						2									2			
								1x 1/36, 1x 2/66								1x 1/36, 1x 2/66								
Sample B		16,0	0,96	6,0	2							2	2	100%	CRV	18,58	0,19	44%	10,4	26,8	2	2	100%	

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E11/21 - Hormones 1

Deadline: 09.02.2021

Test	[unit]	Comparability						Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}		
(306) 17-OH-progesterone	[nmol/L]				2							2	2	100%							2	2	100%	
Samples and groups																								
Sample B		16,0	0,96	6,0	2						2	2	100%	CRV	18,58	0,19	44%	10,4	26,8	2	2	100%		
Other					2	0					2										2			
							1x 1/36, 1x 2/66							1x 1/36, 1x 2/66										
(307) DHEA-S	[µmol/L]				7						7	6	86%								0			
Samples and groups																								
Sample A		8,11	1,8	22	7						7	6	86%								0			
Other					7	0					7													
							3x 4/12, 3x 4/60, 1x 4/179																	
Sample B		7,80	1,9	25	7						7	6	86%								0			
Other					7	0					7													
							3x 4/12, 3x 4/60, 1x 4/179																	

st_kn_np

End of report

Printed: 22.02.2021